This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Picard Medical Presents Artificial Heart Data
Tech medical breakthrough

Picard Medical Presents Artificial Heart Data

Analysis based on 6 articles · First reported Jun 16, 2026 · Last updated Jun 16, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of new data for the Emperor Total Artificial Heart and positive clinical outcomes for the SynCardia Total Artificial Heart could lead to increased investor confidence in Picard Medical, Inc.. This could potentially drive up the stock price of Picard Medical, Inc. as the market anticipates future advancements and broader adoption of their artificial heart technologies.

Medical Devices Biotechnology
Event Summary

Picard Medical, Inc., Inc., through its subsidiary SynCardia Systems, LLC, announced that researchers will present new preclinical data for its next-generation Emperor Total Artificial Heart program and clinical outcomes research for the SynCardia Total Artificial Heart at the American Society for Artificial Internal Organs (ASAIO) 2026 Annual Conference. These presentations, led by Matthew S. Schuster and Richard Smith of SynCardia Systems, will highlight the hemodynamic performance of the Emperor Total Artificial Heart and a holistic analysis of survival, recovery, transplantability, and quality of life for patients supported by the SynCardia Total Artificial Heart. The event underscores Picard Medical, Inc.'s commitment to advancing innovation in mechanical circulatory support and reinforces SynCardia Systems' leadership in artificial heart technology, aiming to expand treatment options for patients with advanced biventricular heart failure.

Entities Involved
priv
Picard Medical, Inc.
Picard Medical, Inc., as the parent company of SynCardia, is announcing the presentation of new data for its next-generation artificial heart and clinical outcomes for its existing product, which could positively impact its market position and stock value.
Importance 100.0 Sentiment 75.0
priv
SynCardia Systems
SynCardia Systems is presenting new preclinical data for its Emperor Total Artificial Heart and clinical outcomes for the SynCardia Total Artificial Heart, reinforcing its leadership in artificial heart technology.
Importance 90.0 Sentiment 70.0
oth
SynCardia Total Artificial Heart
The SynCardia Total Artificial Heart is the world's first FDA and Canada — Health Canada approved artificial heart, and new clinical outcomes research will highlight its real-world impact on patients.
Importance 85.0 Sentiment 65.0
oth
Emperor Total Artificial Heart
The Emperor Total Artificial Heart is SynCardia's next-generation fully implantable motor-driven artificial heart platform, with new in vivo data being presented that could advance its development and future market potential.
Importance 80.0 Sentiment 60.0
ngo
American Society for Artificial Internal Organs
The American Society for Artificial Internal Organs (ASAIO) is hosting the annual conference where Picard Medical, Inc. and SynCardia will present their research, serving as a key forum for artificial organ innovation.
Importance 40.0 Sentiment 0.0
per
Patrick N. J. Schnegelsberg
Patrick N. J. Schnegelsberg, CEO of Picard Medical, Inc., expressed excitement about the presentations, highlighting the company's leadership and vision.
Importance 30.0 Sentiment 0.0
per
Matthew S. Schuster
Matthew S. Schuster, COO of SynCardia and lead inventor of the Emperor Total Artificial Heart, will present data on the Emperor Total Artificial Heart.
Importance 30.0 Sentiment 0.0
per
Richard Smith
Richard Smith, Co-Founder and Scientific Advisor of SynCardia, will present research on patient outcomes with the SynCardia Total Artificial Heart.
Importance 30.0 Sentiment 0.0
govactor
Canada — Health Canada
Canada — Health Canada is mentioned as having approved the SynCardia Total Artificial Heart, indicating regulatory validation in Canada.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration (FDA) is mentioned as having approved the SynCardia Total Artificial Heart, indicating regulatory validation.
Importance 10.0 Sentiment 0.0
Relationships
Canada — Health Canada related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.